다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Therapeutic drug monitoring, v.39 no.3, 2017년, pp.297 - 302
Nakayama, Hirokazu (*Department of Pharmacy, NTT Medical Center Tokyo, Tokyo, Japan) , Echizen, Hirotoshi (†Department of Pharmacotherapy, Meiji Pharmaceutical University, Tokyo, Japan) , Ogawa, Ryuichi (and ‡Gamma Knife Center, NTT Medical Center Tokyo, Tokyo, Japan.) , Akabane, Atsuya , Kato, Toshiaki , Orii, Takao
BACKGROUND:: Phenobarbital is well tolerated and effective for controlling agitation or preventing convulsion at the end of life. No information is available concerning parenteral bioavailability of phenobarbital when induration develops at the injection or infusion site. We investigated whether induration at injection or infusion site is related to phenobarbital bioavailability via parenteral routes of continuous subcutaneous infusion and intermittent subcutaneous or intramuscular injection. METHODS:: A retrospective analysis was conducted on the medical data obtained from 18 patients who received chronic subcutaneous or intramuscular injections of phenobarbital for the prevention of convulsions and underwent plasma concentration monitoring of the drug. Patients whose concomitant medications were altered during the observation periods were excluded from the analysis. Comparisons were performed for concentration/dose (C/D) ratios obtained from patients with induration at injection or infusion sites (induration group, n = 6) and those without induration (noninduration group, n = 12). P < 0.05 was considered statistically significant. RESULTS:: The induration group showed significantly reduced C/D ratio compared with the noninduration group [median (range): 0.131 (0.114–0.334) versus 0.219 (0.180–0.322) d/L, P < 0.05). Assuming that systemic clearance was constant in our patients, changes in the C/D ratio would have contributed to 40% (median) reduction in bioavailability of the drug from the injection or infusion site. CONCLUSIONS:: Our data suggest that absolute bioavailability of phenobarbital may be reduced when induration develops at the injection or infusion site in patients treated parenterally by continuous subcutaneous infusion or intramuscular injection.
Epilepsia Kwan 45 1141 2004 10.1111/j.0013-9580.2004.12704.x Phenobarbital for the treatment of epilepsy in the 21st century: a critical review
Lancet Oncol. Weller 13 e375 2012 10.1016/S1470-2045(12)70266-8 Epilepsy meets cancer: when, why, and what to do about it?
J Pain Symptom Manage. Stirling 17 363 1999 10.1016/S0885-3924(99)00006-8 The use of phenobarbitone in the management of agitation and seizures at the end of life
J Pain Symptom Manage. Cheng 23 256 2002 10.1016/S0885-3924(01)00412-2 When midazolam fails
J Pain Symptom Manage. Storey 5 33 1990 10.1016/S0885-3924(05)80007-7 Subcutaneous infusions for control of cancer symptoms
Am J Hosp Palliat Care. Hosgood 33 209 2016 10.1177/1049909114555157 Evaluation of subcutaneous phenobarbital administration in hospice patients
Epilepsia Bockbrader 52 405 2011 10.1111/j.1528-1167.2010.02763.x Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine
Epilepsia Patsalos 49 1239 2008 10.1111/j.1528-1167.2008.01561.x Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies
J Clin Invest. Waddell 36 1217 1957 10.1172/JCI103518 The distribution and excretion of phenobarbital
Ther Drug Monit. Shipkova 36 433 2014 10.1097/FTD.0000000000000043 Comparability and imprecision of 8 frequently used commercially available immunoassays for therapeutic drug monitoring
Diabetes Care. Johansson 28 2025 2005 10.2337/diacare.28.8.2025 Impaired absorption of insulin aspart from lipohypertrophic injection sites
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.